Of note, the histone‐lysine N‐methyltransferase EZH2 is a novel epigenetic target not previously described, and the ubiquitin‐conjugating enzyme E2C (UBE2C), which belongs to the ubiquitin ligase family of enzymes is also a potentially druggable protein with limited evaluation in ovarian cancer. This evidence concerns the gene UBE2C and ovarian cancer.